Literature DB >> 28451393

The circulating microRNA-200 family in whole blood are potential biomarkers for high-grade serous epithelial ovarian cancer.

Adam Pendlebury1, Natalie J Hannan2, Natalie Binder2, Sally Beard2, Monica Mcgauran2, Peter Grant1, Stephen Tong2, Clare L Whitehead2.   

Abstract

Epithelial ovarian cancer (EOC) is the leading cause of mortality with regard to gynaecological cancer. There is no effective biomarker and therefore prognosis is poor as the majority of cases are not diagnosed until advanced disease is present. MicroRNAs (miRs) are dysregulated in ovarian cancer tissue and are present in the circulation. The aim of the present study was to investigate whether circulating miRs from the miR-200 family served as potential candidate biomarkers for the early detection of EOC. Whole blood and ovarian tissue were collected from women with early (stage I/II, n=4), advanced EOC (stage III/IV, n=4), and women with benign ovarian masses (n=5). A panel of 5 miRs were studied in whole blood and ovarian tissue using Taqman RT-PCR miR assays. The expression of circulating miR-200a, miR-200b and miR-200c were upregulated (P<0.05) in ovarian cancer compared to controls, correlated with the stage of disease and reflected tissue expression. Despite a trend, there was no significant increase in the expression of miR-21 and miR-210 in the present study. In conclusion, the circulating miR-200 family may be promising candidate biomarkers for EOC that require validation in a larger study.

Entities:  

Keywords:  biomarker; epithelial ovarian cancer; microRNA

Year:  2017        PMID: 28451393      PMCID: PMC5403187          DOI: 10.3892/br.2017.847

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  13 in total

1.  Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.

Authors:  M Zuberi; R Mir; J Das; I Ahmad; J Javid; P Yadav; M Masroor; S Ahmad; P C Ray; A Saxena
Journal:  Clin Transl Oncol       Date:  2015-06-11       Impact factor: 3.405

Review 2.  Hypoxia--a key regulatory factor in tumour growth.

Authors:  Adrian L Harris
Journal:  Nat Rev Cancer       Date:  2002-01       Impact factor: 60.716

3.  Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease.

Authors:  Sang Wun Kim; Jae Wook Kim; Young Tae Kim; Jae Hoon Kim; Sunghoon Kim; Bo Sung Yoon; Eun Ji Nam; Hye Yeon Kim
Journal:  Genes Chromosomes Cancer       Date:  2007-01       Impact factor: 5.006

4.  Hypoxia-induced miR-210 in epithelial ovarian cancer enhances cancer cell viability via promoting proliferation and inhibiting apoptosis.

Authors:  Li'an Li; Ke Huang; Yanqin You; Xiaoyu Fu; Lingyun Hu; Lei Song; Yuanguang Meng
Journal:  Int J Oncol       Date:  2014-04-04       Impact factor: 5.650

5.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

6.  Human epididymis protein 4 expression positively correlated with miR-21 and served as a prognostic indicator in ovarian cancer.

Authors:  Yong Chen; Qingquan Chen; Qicai Liu; Feng Gao
Journal:  Tumour Biol       Date:  2016-01-05

7.  Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition.

Authors:  Ausra Bendoraite; Emily C Knouf; Kavita S Garg; Rachael K Parkin; Evan M Kroh; Kathy C O'Briant; Aviva P Ventura; Andrew K Godwin; Beth Y Karlan; Charles W Drescher; Nicole Urban; Beatrice S Knudsen; Muneesh Tewari
Journal:  Gynecol Oncol       Date:  2009-10-24       Impact factor: 5.482

8.  Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: results and 5-year follow-up.

Authors:  Heinz S Scholz; Hülya Tasdemir; Tobias Hunlich; Wolfram Turnwald; Armin Both; Herwig Egger
Journal:  Gynecol Oncol       Date:  2007-07-09       Impact factor: 5.482

9.  Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.

Authors:  Saundra S Buys; Edward Partridge; Amanda Black; Christine C Johnson; Lois Lamerato; Claudine Isaacs; Douglas J Reding; Robert T Greenlee; Lance A Yokochi; Bruce Kessel; E David Crawford; Timothy R Church; Gerald L Andriole; Joel L Weissfeld; Mona N Fouad; David Chia; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Patricia Hartge; Paul F Pinsky; Claire S Zhu; Grant Izmirlian; Barnett S Kramer; Anthony B Miller; Jian-Lun Xu; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  JAMA       Date:  2011-06-08       Impact factor: 157.335

Review 10.  MicroRNA: a new and promising potential biomarker for diagnosis and prognosis of ovarian cancer.

Authors:  Manish K Pal; Shyam P Jaiswar; Vinaya N Dwivedi; Amit K Tripathi; Ashish Dwivedi; Pushplata Sankhwar
Journal:  Cancer Biol Med       Date:  2015-12       Impact factor: 4.248

View more
  12 in total

Review 1.  Serum Biomarker Based Algorithms in Diagnosis of Ovarian Cancer: A Review.

Authors:  Suchitra Kumari
Journal:  Indian J Clin Biochem       Date:  2018-08-06

2.  MicroRNA-200a induces apoptosis by targeting ZEB2 in alcoholic liver disease.

Authors:  Yu-Xin Zhao; Ying-Yin Sun; Ai-Ling Huang; Xiao-Feng Li; Cheng Huang; Tao-Tao Ma; Jun Li
Journal:  Cell Cycle       Date:  2018-01-15       Impact factor: 4.534

Review 3.  Surveillance of Tumour Development: The Relationship Between Tumour-Associated RNAs and Ribonucleases.

Authors:  Nadezhda Mironova; Valentin Vlassov
Journal:  Front Pharmacol       Date:  2019-09-13       Impact factor: 5.810

4.  Transcriptomic analysis of patient plasma reveals circulating miR200c as a potential biomarker for high-grade serous ovarian cancer.

Authors:  Natalie J Hannan; Paul A Cohen; Sally Beard; Sanela Bilic; Bonnie Zhang; Stephen Tong; Clare Whitehead; Lisa Hui
Journal:  Gynecol Oncol Rep       Date:  2021-12-02

5.  Extracellular Vesicles from Uterine Aspirates Represent a Promising Source for Screening Markers of Gynecologic Cancers.

Authors:  Gleb O Skryabin; Andrey V Komelkov; Kirill I Zhordania; Dmitry V Bagrov; Svetlana V Vinokurova; Sergey A Galetsky; Nadezhda V Elkina; Darya A Denisova; Adel D Enikeev; Elena M Tchevkina
Journal:  Cells       Date:  2022-03-22       Impact factor: 6.600

6.  High Expression of MicroRNA-200a/b Indicates Potential Diagnostic and Prognostic Biomarkers in Epithelial Ovarian Cancer.

Authors:  Beilei Zhang; Yi Li; Yanhong Li; Hongxi Zhao; Ruifang An
Journal:  Dis Markers       Date:  2022-03-25       Impact factor: 3.434

Review 7.  The miR-200 Family of microRNAs: Fine Tuners of Epithelial-Mesenchymal Transition and Circulating Cancer Biomarkers.

Authors:  Ilaria Cavallari; Francesco Ciccarese; Evgeniya Sharova; Loredana Urso; Vittoria Raimondi; Micol Silic-Benussi; Donna M D'Agostino; Vincenzo Ciminale
Journal:  Cancers (Basel)       Date:  2021-11-23       Impact factor: 6.639

Review 8.  Recent advances of non-coding RNAs in ovarian cancer prognosis and therapeutics.

Authors:  Mengyu Chen; Ningjing Lei; Wanjia Tian; Yong Li; Lei Chang
Journal:  Ther Adv Med Oncol       Date:  2022-08-12       Impact factor: 5.485

9.  Integrated extracellular microRNA profiling for ovarian cancer screening.

Authors:  Akira Yokoi; Juntaro Matsuzaki; Yusuke Yamamoto; Yutaka Yoneoka; Kenta Takahashi; Hanako Shimizu; Takashi Uehara; Mitsuya Ishikawa; Shun-Ichi Ikeda; Takumi Sonoda; Junpei Kawauchi; Satoko Takizawa; Yoshiaki Aoki; Shumpei Niida; Hiromi Sakamoto; Ken Kato; Tomoyasu Kato; Takahiro Ochiya
Journal:  Nat Commun       Date:  2018-10-17       Impact factor: 14.919

10.  Defining fallopian tube-derived miRNA cancer signatures.

Authors:  Selam B Dejene; Anders W Ohman; Wei Du; Deepinder Randhawa; Anand Bradley; Niraj Yadav; Kevin M Elias; Daniela M Dinulescu; Sunita R Setlur
Journal:  Cancer Med       Date:  2019-09-10       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.